JHL Biotech's Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer
Shots:
- JHL1188 gets CHMP approval for its global Phase III clinical trial in metastatic breast cancer
- JHL1188 is a proposed biosimilar to trastuzumab- which is marketed by Roche under the trade name Herceptin
- JHL is developing 7 biosimilar including JHL1188- which is for metastatic breast cancer
Ref: Prnewswire | Image: BioSpectrum Asia
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
